Physician profile
Michael Jordan
NPI 1295724839
$5,608.11
in general payments reported to CMS, 2019-2025
13 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 92% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $49.81 · 2021: $1,362 · 2022: $82.55 · 2023: $1,157 · 2024: $32.40 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,298 · Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,298.49 |
| Food and Beverage | $544.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $2,775.88 | 2023-2025 | |
| Peerless Surgical INC. | $2,430.46 | 2019-2021 | |
| Sebela Pharmaceuticals INC. | $127.27 | 2019-2023 | Naftin |
| Paratek Pharmaceuticals, INC. | $62.16 | 2022-2024 | Nuzyra |
| Orthofix Medical, INC. | $34.55 | 2020 | |
| Paragon 28, INC. | $31.64 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $26.92 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $24.76 | 2022-2023 | Seglentis |
| Nabriva Therapeutics, Plc | $24.45 | 2021 | |
| Alfasigma USA, INC. | $20.35 | 2021 | |
| Anika Therapeutics, INC. | $17.95 | 2022 | |
| Bioventus LLC | $15.92 | 2021 | |
| Osiris Therapeutics INC. | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.